Abstract
Background: Indications for the use of cytomegalovirus (CMV)-negative and irradiated blood products (IRBP) are not standardized and are often poorly understood by providers. This project evaluated the use of a transfusion algorithm in an outpatient oncology clinic to reduce the risk of transfusion-associated graft-vs.-host disease (TA-GVHD) and eliminate the improper use of CMV-negative and irradiated blood products. Objectives: The aim of this project was to increase the correct use of CMV-negative and irradiated blood products at an outpatient oncology clinic by establishing a transfusion algorithm, to evaluate the effectiveness of clinical transfusion algorithms on the use of specialty blood products, and to educate providers on TA-GVHD. Methods: This quasi-experimental project compared 12 weeks of transfusion data before the implementation of a transfusion algorithm to 12 weeks of transfusion data after the algorithm was introduced. A pre- and post-test survey measured the satisfaction and the impact of the education. Findings: The transfusion algorithm resulted in a clinically significant increase in the correct use of both CMV-negative and irradiated blood products at an outpatient oncology clinic. The education in-services provided to staff about TA-GVHD and the indications for irradiated blood product resulted in a significant increase in provider knowledge on ordering specialty blood products.
References
American Red Cross. (2022). What is CMV negative blood? Why is it important. https://www.redcrossblood.org/local-homepage/news/article/why-cmv-negative-blood-is-so-important.html
Bahar, B., & Tormey, C. A. (2018). Prevention of transfusion-associated graft-versus-host disease with blood product irradiation: The past, present, and future. Archives of Pathology & Laboratory Medicine, 142(5), 662–667. https://doi.org/10.5858/arpa.2016-0620-RS(Blood Bank Guy)
Elemary, M., Seghatchian, J., Stakiw, J., Bosch, M., Sabry, W., & Goubran, H. (2017). Transfusion challenges in hematology oncology and hematopoietic stem cell transplant: Literature review and local experience. Transfusion and Apheresis Science, 56(3), 317–321. https://doi.org/10.1016/j.transci.2017.05.022(SCIRP)
Foukaneli, T., Kerr, P., Bolton-Maggs, P. H. B., Cardigan, R., Coles, A., Gennery, A., Jane, D., Kumararatne, D., Manson, A., New, H. V., & Torpey, N. (2020). Guidelines on the use of irradiated blood components. British Journal of Haematology, 191(5), 704–724. https://doi.org/10.1111/bjh.17015(SpringerLink)
Gupta, S., Sengal, T., Sachdeva, M. W. S., Nasem, S., Das, F., & Nada, R. (2016). Transfusion-associated graft-versus-host disease with a non-fatal course. Indian Journal of Hematology and Blood Transfusion, 32(4), 326–328. https://doi.org/10.1007/s12288-016-0677-3
Harris, A. D., McGregor, J. C., Perencevich, E. N., Furuno, J. P., Zhu, J., Peterson, D. E., & Finkelstein, J. (2006). The use and interpretation of quasi-experimental studies in medical informatics. Journal of the American Medical Informatics Association, 13(1), 16–23. https://doi.org/10.1197/jamia.M1749(Johns Hopkins University)
Patel, K. K., Patel, A. K., Ranjan, R. R., & Shah, A. P. (2010). Transfusion associated graft versus host disease following whole blood transfusion from an unrelated donor in an immunocompetent patient. Indian Journal of Hematology and Blood Transfusion, 26(3), 92–95. https://doi.org/10.1007/s12288-010-0028-0
Prokopchuk-Gauk O, Solh Z. Irradiated, washed and CMV seronegative blood components. In: Khandelwal A, Abe T, editors. Clinical Guide to Transfusion [Internet]. Ottawa: Canadian Blood Services, 2021. Chapter 15. https://professionaleducation.blood.ca/en/transfusion/clinical-guide/irradiated-washed-and-cmv-seronegative-blood-components
